Reuters reports Biogen revealed the Federal Trade Commission asked the company “to present documents related to the approval and marketing of its Alzheimer’s disease treatment,” Aduhelm, which is a civil investigative demand that is “similar to a subpoena.” The company “also received an inquiry from the U.S. Securities and Exchange Commission seeking information over Aduhelm, which received a controversial approval last year.” Reuters explains that the FDA approved the drug in June of last year “despite a panel of its expert advisers voting against the drug, leading to some of the panel members resigning and U.S. lawmakers launching an investigation into the drug.”

From the news release of the American Association for Justice.